Doxribtimine

Doxribtimine

SCHEMBL8075845

Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O.Cc1cn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)[nH]c1=O.O=P(O)(O)O

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

P

The experimentally established mechanism targets of Doxribtimine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
TK1 P04183 4/20 0.67
LMNA P02545 3/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
POLB P06746 1/20 0.67
TK2 O00142 1/20 0.65
TSHR P16473 2/20 0.65
ALB P02768 1/20 0.65
PKM P14618 1/20 0.65
BLM P54132 1/20 0.65
PMP22 Q01453 1/20 0.65
CYP2D6 P10635 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Doxribtimine SCHEMBL887722 1.00 TK1 (0.67) TK1LMNASMN1; SMN2POLBTK2
Doxribtimine SCHEMBL77830 1.00 TK1 (0.67) TK1LMNASMN1; SMN2POLBTK2
Doxribtimine SCHEMBL176363 1.00 TK1 (0.67) TK1LMNASMN1; SMN2POLBTK2
Doxribtimine SCHEMBL21682515 1.00 TK1 (0.67) TK1LMNASMN1; SMN2POLBTK2
Doxribtimine SCHEMBL9687292 0.99 TK1 (0.66) TK1LMNASMN1; SMN2POLBTK2
Doxribtimine SCHEMBL29150139 0.98 TK1 (0.65) TK1LMNASMN1; SMN2POLBTK2
Doxribtimine SCHEMBL7576317 0.97 TK1 (0.66) TK1LMNASMN1; SMN2POLBTK2
Doxribtimine SCHEMBL5692278 0.97 TK1 (0.66) TK1LMNASMN1; SMN2POLBTK2
Doxribtimine SCHEMBL9386574 0.97 TK1 (0.66) TK1LMNASMN1; SMN2POLBTK2
Doxribtimine SCHEMBL9385913 0.97 TK1 (0.66) TK1LMNASMN1; SMN2POLBTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4146280-A1 LINKER COMPOUNDS Mpeg LA, L.l.c. (US) 2023-03-15 EP disclosed
CN-115515968-A Allele-specific silencing of transforming growth factor beta-inducible genes with R124H mutation using short interfering RNA 阿维利诺美国实验室股份有限公司 2022-12-23 CN disclosed
US-6124445-A PRO DRUGS FOR OLIGONUCLEOTIDES HAVING BIOREVERSIBLE PHOSPHATE BLOCKING GROUPS ISIS PHARMACEUTICALS, INC. (US) 2000-09-26 US disclosed
US-5955591-A OLIGONUCLEOTIDES HAVING BIOREVERSIBLE PHOSPHATE BLOCKING GROUPS; USED AS PRODRUGS; ANTISENSE AGENTS CENTER NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1999-09-21 US disclosed
EP-0912592-A1 PHOSPHOTRIESTER OLIGONUCLEOTIDES, AMIDITES AND METHOD OF PREPARATION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1999-05-06 EP disclosed
US-5750666-A FOR SYNTHESIZING NEW MONONUCLEOTIDES AND POLYNUCLEOTIDES HAVING PHOSPHOROTHIOATE AND PHOSPHORODITHIOATE INTERNUCLEOTIDE LINKAGES COMPETITVE TECHNOLOGIES, INC. (US) 1998-05-12 US disclosed
WO-1997047637-A1 PHOSPHOTRIESTER OLIGONUCLEOTIDES, AMIDITES AND METHOD OF PREPARATION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (US) 1997-12-18 WO disclosed
US-5684148-A NUCLEOSIDES AND POLYNUCLEOTIDES AS FLUORESCENT AGENTS FOR MEDICAL DIAGNOSIS COMPETITIVE TECHNOLOGIES, INC. (US) 1997-11-04 US disclosed
US-5637683-A REACTING AN AMINE HAVING BASE SELECTED FROM URACIL, ADENINE, GUANINE, CYTOSINE, THYMINE, OR HYPOXANTHINE, WITH PENTAFLUOROPHENYL ESTER DERIVATIVE TO FORM INTERMEDIATE, REACTING INTERMEDIATE WITH ADDITIONAL AMINE CORNELL RESEARCH FOUNDATION, INC. (US) 1997-06-10 US disclosed
US-5602244-A DINUCLEOSIDE PRECURSORS IN OLIGONUCLEOTIDE SYNTHESIS; USEFUL AS ANTISENSE INHIBITORS OF TRANSLATION COMPETITIVE TECHNOLOGIES, INC. (US) 1997-02-11 US disclosed
US-5548076-A CONDENSING A BLOCKED NUCLEOSIDE BOUND TO A CARRIER GENENTECH, INC. (US) 1996-08-20 US disclosed
EP-0219342-B1 Method and reagents for in vitro oligonucleotide synthesis GENENTECH INC (US) 1994-03-16 EP disclosed
US-5264566-A Method for in vitro oligonucleotide synthesis using H-phosphonates GENENTECH, INC. (US) 1993-11-23 US disclosed
US-5218103-A Nucleoside thiophosphoramidites UNIVERSITY PATENTS, INC. (US) 1993-06-08 US disclosed
EP-0378615-A4 NUCLEOSIDE AND POLYNUCLEOTIDE THIOPHOSPHORAMIDITE AND PHOSPHORODITHIOATE COMPOUNDS AND PROCESSES 1992-04-08 EP disclosed
WO-1991004983-A1 NUCLEOSIDE AND POLYNUCLEOTIDE THIOPHOSPHORAMIDITE AND PHOSPHORODITHIOATE COMPOUNDS AND PROCESSES UNIVERSITY PATENTS, INC. (US) 1991-04-18 WO disclosed
US-4959463-A Intermediates GENENTECH, INC. (US) 1990-09-25 US disclosed
EP-0378615-A1 NUCLEOSIDE AND POLYNUCLEOTIDE THIOPHOSPHORAMIDITE AND PHOSPHORODITHIOATE COMPOUNDS AND PROCESSES COMPETITIVE TECHNOLOGIES INC. (US) 1990-07-25 EP disclosed
WO-1989011486-A1 NUCLEOSIDE AND POLYNUCLEOTIDE THIOPHOSPHORAMIDITE AND PHOSPHORODITHIOATE COMPOUNDS AND PROCESSES UNIVERSITY PATENTS, INC. (US) 1989-11-30 WO disclosed
EP-0219342-A2 Method and reagents for in vitro oligonucleotide synthesis GENENTECH, INC. (US) 1987-04-22 EP disclosed